Break the 10 per cent retirement planning rule
Break the 10 per cent retirement planning rule

Break the 10 per cent retirement planning rule

Henil Shah Article rating: 3.5

Not all rules are meant to be broken as they may dent your pocket heavily. However, in this article, we would be explaining why you should break the 10 per cent retirement planning rule.

Reliance share zooms on joining hands with BP to set up second new deepwater gas field
Reliance share zooms on joining hands with BP to set up second new deepwater gas field

Reliance share zooms on joining hands with BP to set up second new deepwater gas field

Shreya Chaware Article rating: 3.7

Reliance Industries Limited (RIL) informed today that it has collaborated with BP, one of the world's seven oil & gas ‘supermajors’ and British multinational company to commence production from the Satellite Cluster Gas Field in block KG D6, off the east coast of India.  

Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab
Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab

Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab

Apurva Joshi Article rating: 5.0

Biocon Limited’s subsidiary Biocon Biologics Ltd has informed the bourses that Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. has received marketing authorisation approval from European Commission (EC), following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. 

Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent
Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent

Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent

Abhinav Lahoti Article rating: 3.8

The company today announced that it has applied to Central Drugs Standard Control Organisation (CDSCO) of India for the approval of phase 3 clinical trials of ‘Molnupiravir’ capsules, which have shown promising results during the treatment of COVID-19 positive patient. 

In conversation with Mahesh Patil, Chief Investment Officer of Aditya Birla Sun Life AMC Ltd
In conversation with Mahesh Patil, Chief Investment Officer of Aditya Birla Sun Life AMC Ltd

In conversation with Mahesh Patil, Chief Investment Officer of Aditya Birla Sun Life AMC Ltd

Shashikant Singh Article rating: 3.7

We follow a ‘growth at a reasonable price (GARP) investing style’ since it combines the best of both worlds. We have identified themes that provide secular growth opportunities such as private banks, unorganised to organised, speciality chemicals, manufacturing in India, and technology/digital.

NFO analysis: Canara Robeco Focused Equity Fund
NFO analysis: Canara Robeco Focused Equity Fund

NFO analysis: Canara Robeco Focused Equity Fund

Henil Shah Article rating: 3.8

Canara Robeco has launched its Canara Robeco Focused Equity Fund and is currently opened for subscription. Read onto find out more about it.

Hester Biosciences embarks on a new range of herbal veterinary products
Hester Biosciences embarks on a new range of herbal veterinary products

Hester Biosciences embarks on a new range of herbal veterinary products

Anthony Fernandes Article rating: 5.0

Following the global trend of medication shifting from allopathy to herbal therapy in veterinary, Hester Biosciences announced on Saturday that it has embarked on a journey to produce research-based herbal products for livestock and poultry.  

Does investing in direct plans via RIA make sense?
Does investing in direct plans via RIA make sense?

Does investing in direct plans via RIA make sense?

Henil Shah Article rating: 3.6

SEBI registered investment advisers (RIAs) do promote direct plans in mutual funds a lot. So, does it make sense to invest in direct plans via them? Let’s find out.

RSS
First22042205220622072209221122122213Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR